Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Non-Current Deffered Revenue (2023 - 2024)

Gain Therapeutics has reported Non-Current Deffered Revenue over the past 2 years, most recently at $47441.0 for Q4 2024.

  • Quarterly results put Non-Current Deffered Revenue at $47441.0 for Q4 2024, down 49.95% from a year ago — trailing twelve months through Dec 2024 was $47441.0 (down 49.95% YoY), and the annual figure for FY2024 was $47441.0, down 49.95%.
  • Non-Current Deffered Revenue for Q4 2024 was $47441.0 at Gain Therapeutics, down from $65869.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for GANX hit a ceiling of $608982.0 in Q2 2023 and a floor of $47441.0 in Q4 2024.